

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

Application Number	10/583,927
Filing Date	December 23, 2004
First Named Inventor	Sek Chung Fung
Art Unit	1643
Examiner Name	Stephen L. Rawlings
Attorney Docket No.	12279-187-999

FOREIGN PATENT DOCUMENTS

*Examiner Initials	Cite No.	Foreign Patent Document Country Code, Number, Kind Code (if known)	Publication Date mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
Change(s) applied to document, /MAH/ 8/30/2011	B30	WO 00/44407 A2	8/03/2000	Amgen Canada		
	B31	WO 01/34645 A2	5/17/2001	The Govt of the USA		
	B32	WO 01/92514 A1	6/12/2001	Shanghai Biowindow Gene Development Inc.		
	B33	WO 03/035847 A2	5/01/2003	Centocor, Inc.		
	B34	WO 03/086451 A1	10/23/2003	Centocor, Inc.		
	B35	WO 2003/040164 A2	5/15/2003	Cytos Biotechnology AG [CH]		
	B36	WO 2004/001655 A1	12/31/2003	Office of Technology Transfer, Dept. of Health and Human Services representing Government of United States of America		
	B37	WO 2004/019974 A2	3/11/2004	Glaxo Group Ltd [GB]		
	B38	WO 2004/019979 A2	3/11/2004	Glaxo Group Ltd [GB]		
	B39	WO 2005/121177 A2	12/22/2005	Wyeth		
	B40	WO 2005/123126 A2	12/29/2005	Wyeth		
	B41	WO 2007/036745 (A2,A3)	04/05/2007	Cambridge Antibody Tech [GB] et al.		
	B42	WO 2007/045477 (A2, A3)	04/26/2007	Novartis AG [CH] ; Novartis Pharma GMBH [AT]		

NON PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C72	"Monoclonal Anti-Human IL 13 Antibody," R&D Systems, Inc. Catalog [on-line], October 2002 [retrieved on October 14, 2002], Retrieved from the Internet:< URL: http://www.rndsystems.com/asp/c_search.asp?ucategory=3&factors=IL%2D13 >.	
	C73	AHLERS et al., 2002, "A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L." Proc Natl Acad Sci U S A; 99(20):13020-5	
	C74	AKBARI et al., 2003, "Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity." Nat Med. 9(5):582-8	
	C75	ALBERTS et al., 1994, "An antibody molecule is composed of two identical light chains and two identical heavy chains," Molecular Biology of the Cell, Third Edition, Garland Publishing, Inc., New York, pp. 1208-1209	
	C76	AMRAD CORPORATION, Ltd. "IL-13 Receptor Antibody Project." August 17, 2005	
	C77	ARIMA et al., 2002, "Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma." J Allergy Clin Immunol. 109(6):980-7	
	C78	ARIMA et al., 2005, "Characterization of the interaction between interleukin-13 and interleukin-13 receptors". J. Biol. Chem. Vol. 280(26):24915-24922	

NYI-4245742

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SR/